Abstract
Treatment of pediatric oncology patients generally results in
significant immunosuppression and when the COVID-19 pandemic arose,
there was concern among pediatric oncologists about the implications of
this virus. We reviewed the literature and describe all pediatric
oncology patients with COVID-19 reported worldwide. Within this review,
it is striking that CNS tumors are reported at low numbers (27/466
pediatric oncology patients with COVID-19). This may be related to
decreased inpatient care when compared to other pediatric cancers.
Additional work is needed to understand the risk of infection in this
population and gain insight into the effect on delivery of oncology
care.